ENLV
Price
$0.88
Change
-$0.07 (-7.37%)
Updated
Apr 4, 02:30 PM (EDT)
Capitalization
22.38M
49 days until earnings call
FATE
Price
$0.72
Change
+$0.04 (+5.88%)
Updated
Apr 4, 04:31 PM (EDT)
Capitalization
78.95M
26 days until earnings call
Ad is loading...

ENLV vs FATE

Header iconENLV vs FATE Comparison
Open Charts ENLV vs FATEBanner chart's image
Enlivex Therapeutics
Price$0.88
Change-$0.07 (-7.37%)
Volume$100
Capitalization22.38M
Fate Therapeutics
Price$0.72
Change+$0.04 (+5.88%)
Volume$4.57K
Capitalization78.95M
ENLV vs FATE Comparison Chart
Loading...
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENLV vs. FATE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a Hold and FATE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ENLV: $0.95 vs. FATE: $0.68)
Brand notoriety: ENLV and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENLV: 40% vs. FATE: 107%
Market capitalization -- ENLV: $22.38M vs. FATE: $78.95M
ENLV [@Biotechnology] is valued at $22.38M. FATE’s [@Biotechnology] market capitalization is $78.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENLV’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ENLV’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ENLV and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENLV’s TA Score shows that 3 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • ENLV’s TA Score: 3 bullish, 7 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ENLV.

Price Growth

ENLV (@Biotechnology) experienced а -6.30% price change this week, while FATE (@Biotechnology) price change was -22.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.29%. For the same industry, the average monthly price growth was -17.13%, and the average quarterly price growth was -18.92%.

Reported Earning Dates

ENLV is expected to report earnings on May 23, 2025.

FATE is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-11.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($78.9M) has a higher market cap than ENLV($22.4M). ENLV YTD gains are higher at: -19.111 vs. FATE (-58.788). ENLV has higher annual earnings (EBITDA): -15.44M vs. FATE (-176.58M). FATE has more cash in the bank: 279M vs. ENLV (24.5M). ENLV has less debt than FATE: ENLV (765K) vs FATE (85.3M). FATE has higher revenues than ENLV: FATE (13.6M) vs ENLV (0).
ENLVFATEENLV / FATE
Capitalization22.4M78.9M28%
EBITDA-15.44M-176.58M9%
Gain YTD-19.111-58.78833%
P/E RatioN/AN/A-
Revenue013.6M-
Total Cash24.5M279M9%
Total Debt765K85.3M1%
FUNDAMENTALS RATINGS
ENLV vs FATE: Fundamental Ratings
ENLV
FATE
OUTLOOK RATING
1..100
7357
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
8596
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as ENLV (22) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as ENLV (98) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

ENLV's Price Growth Rating (85) in the Medical Specialties industry is in the same range as FATE (96) in the Biotechnology industry. This means that ENLV’s stock grew similarly to FATE’s over the last 12 months.

ENLV's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as FATE (100) in the Biotechnology industry. This means that ENLV’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENLVFATE
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 26 days ago
75%
Bullish Trend 24 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSCO55.770.15
+0.27%
Tractor Supply Co
BCSF16.23-0.22
-1.34%
Bain Capital Specialty Finance
RELY20.13-1.25
-5.85%
Remitly Global
CTRM2.14-0.17
-7.52%
Castor Maritime
AKYA1.22-0.14
-10.29%
Akoya BioSciences

ENLV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENLV
1D Price
Change %
ENLV100%
-6.30%
APVO - ENLV
39%
Loosely correlated
+44.20%
FATE - ENLV
32%
Poorly correlated
-11.69%
VKTX - ENLV
30%
Poorly correlated
-5.69%
SLNO - ENLV
29%
Poorly correlated
-2.05%
AXON - ENLV
29%
Poorly correlated
-3.35%
More